Sequence information
DRAVP ID DRAVPc024
Name Bulevirtide
Sequence
Molecular Formula Not Available
Condition/Disease Chronic Hepatitis D infection
Group Approved(HDV)
Type Preptide
Description The N-terminal of Bulevirtide is tetradecanoylglycyl and C-terminal is amide. Bulevirtide is a drug for the treatment of chronic Hepatitis D infection in adults with compensated liver disease.Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.
Active sequence/Structure
External Links
DrugBank Accession Number DB15248
Pubchem ID 381128209
CHEMBL ID CHEMBL4297711
UNII WKM56H3TLB
CAS 2012558-47-1
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT02888106 | Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent | Chronic Viral Hepatitis B With Delta-agent Treatment | Completed | Phase 2 | Hepatera Ltd. |
| NCT03852433 | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | Chronic Hepatitis Delta | Completed | Phase 2 | Gilead Sciences |
